Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPN1 | P15169 | 2/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 10/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21578335 | 0.79 | F2 (0.34) | CPN1CPB2F2PRSS1PLG | |
| SCHEMBL5858917 | 0.73 | F2 (0.38) | F2PRSS1ITGB3ITGA2B | |
| SCHEMBL661207 | 0.72 | CPN1 (0.50) | CPN1CPB2F2PRSS1ITGB3 | |
| SCHEMBL4955491 | 0.71 | LTA4H (0.33) | — | |
| SCHEMBL3260894 | 0.67 | ACE (0.45) | — | |
| SCHEMBL18528443 | 0.67 | ITGB3 (0.46) | F2PRSS1ITGB3ITGA2BPOLB | |
| SCHEMBL919280 | 0.66 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL147119 | 0.66 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL147120 | 0.66 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL1468174 | 0.64 | ALDH1A1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015306-B2 | Labeled neurotensin derivatives | BIOSYNTHEMA, INC. (US) | 2006-03-21 | — | — | US | disclosed |
| US-20050191240-A1 | Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes | ADVANCED ACCELERATOR APPLICATIONS USA, INC. | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050191240-A1 | Peptide analogs of neurotensin resistant to enzymatic degradation and retain high binding affinity for neurotensin receptors; metal chelating group on one end; replacing Arg8 with Gly(PipAm) ((N-amidinopiperidinyl)glycine) for example; useful for diagnostic and therapeutic purposes | ANPEP, DNPEP, NTSR1 | CPN1 49/4885CPB2 516/4885F2 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.